Takeda Pharmaceutical Company Limited recently announced the completion of its acquisition of Shire plc on January 8, 2019. The acquisition was approved by an overwhelming majority of their shareholders on December 5, 2018.
“We appreciate the support of our employees, partners and shareholders throughout the process. This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicines to patients around the world with expanded scale and geographical footprint,” said Christopher Weber, President and Chief Executive Officer of Takeda.
Headquartered in Japan, Takeda is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing both better health and a brighter future to patients. Their efforts are focused on oncology, gastroenterology (GI), neuroscience, rare disease, and a targeted focus on plasma-derived therapies (PDT) and vaccines.
Takeda is dedicated to maintaining their commitment to providing exceptional patient support and partnering with patient advocacy organizations. Now in approximately 80 countries/regions worldwide, they believe their strengthened R&D engine, expanded portfolio of innovative products and consistent values will enable them to develop and deliver highly-innovative, transformative medicines to more patients.
Weber continued, “The execution of our integration begins today, and we are confident in our ability to execute a smooth integration under the leadership of our experienced and diverse Takeda executive team with a strong track record. The operating model we established in September last year has set a clear framework for our integration plans, and we have a highly skilled and dedicated integration team leading the process.”
The company stressed that all US-based patient services personnel remain in place and can be reached using existing phone and web-based methods.